(TSX:SJ), MONTRÉAL, Aug. 06, 2025 (GLOBE NEWSWIRE) — Stella-Jones Inc. (TSX: SJ). OPEN TO: Investors, analysts and all interested parties DATE: Thursday, August 7, 2025 TIME: 10:00 AM Eastern Daylight Time LIVE WEBCAST: https://meetings.lumiconnect.com/400-675-688-704 CALL: 1-800-206-4400 THE PRESS RELEASE WILL BE PUBLISHED BEFORE MARKET OPENS THE DAY OF THE CONFERENCE CALL THROUGH GLOBE NEWSWIRE. Please […]

(TASE:KMDA.TA),(NASDAQ:KMDA), REHOVOT, Israel, and HOBOKEN, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) — Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a commercial stage global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the second

(NASDAQ:BCRX), RESEARCH TRIANGLE PARK, N.C., Aug. 06, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted 10 newly-hired employees stock options to purchase an aggregate of 36,700 shares, and restricted stock units (RSUs) covering an aggregate of 89,750 shares, of BioCryst common stock.

USA Rare Earth to Present at the Canaccord Genuity 45th Annual Growth Conference GlobeNewswire August 06, 2025 STILLWATER, Okla., Aug. 06, 2025 (GLOBE NEWSWIRE) — USA Rare Earth, Inc. (Nasdaq: USAR) (USAR or the Company), today announced that W. Robert Steele, Chief Financial Officer, will present at the Canaccord Genuity 45th Annual Growth Conference on

(NasdaqGM:TRDA), — First patient dosed in ELEVATE-44-201 with data from first patient cohort anticipated in H1 2026 — — Initiated ELEVATE-45-201 and on track to dose the first patient in Q3 2025 — — Multiple clinical trial sites in U.K. and EU activated for ELEVATE-44-201 and ELEVATE-45-201 — — Leadership team expanded with the additions

(NASDAQ:ASTE), Second Quarter 2025 Overview (all comparisons are made to the corresponding prior year second quarter unless otherwise specified): Net sales of $330.3 million Net income of $16.7 million; Adjusted net income of $20.3 million EBITDA of $29.0 million; Adjusted EBITDA of $33.7 million Diluted EPS of $0.72; Adjusted EPS of $0.88 Operating cash flow

(NasdaqGM:NAMS),(NasdaqGM:NAMSW), -European marketing authorization application on track in 2H25 – – PREVAIL Phase 3 CVOT remains on track – – Late Breaking BROADWAY and TANDEM data presented at EAS 2025 and simultaneously published in The New England Journal of Medicine (BROADWAY) and The Lancet (TANDEM) – – BROADWAY Alzheimer's disease analysis presented at AAIC 2025

Purple Biotech Reports Second Quarter 2025 Financial Results GlobeNewswire August 06, 2025 Platform validating preclinical data presented at EACR 2025 for CAPTN-3 tri-specific T cell engager show synergistic activity of the platform's masked CD3, NKG2A, and tumor-associated antigen arms First CAPTN-3 trispecific antibody targeting novel tumor associated antigen, 5T4, advances toward first-in-human clinical trials, with

(NYSE MKT:AMS), SAN FRANCISCO, Aug. 06, 2025 (GLOBE NEWSWIRE) — American Shared Hospital Services (NYSE American: AMS) (the “Company”), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its leasing and direct patient care services segments, today announced that the Company will hold a conference call to discuss its

PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics ('OMass' or 'the Company'), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A.